{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:21:56Z","timestamp":1767140516963,"version":"build-2238731810"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2013,5,30]],"date-time":"2013-05-30T00:00:00Z","timestamp":1369872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"DOI":"10.1007\/s10198-013-0486-z","type":"journal-article","created":{"date-parts":[[2013,5,29]],"date-time":"2013-05-29T10:05:58Z","timestamp":1369821958000},"source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness of febuxostat in chronic gout"],"prefix":"10.1007","author":[{"given":"Stephen M.","family":"Beard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgitta G.","family":"von Scheele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Nuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isobel V.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,30]]},"reference":[{"key":"486_CR1","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/rheumatology\/kem150","volume":"46","author":"E Roddy","year":"2007","unstructured":"Roddy, E., Zhang, W., Doherty, M.: Is gout associated with reduced quality of life? A case-control study. Rheumatology (Oxford) 46, 1441\u20131444 (2007)","journal-title":"Rheumatology (Oxford)"},{"key":"486_CR2","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s11136-008-9355-0","volume":"17","author":"D Khanna","year":"2008","unstructured":"Khanna, D., Ahmed, M., Yontz, D., et al.: The disutility of chronic gout. Qual. Life Res. 17, 815\u2013822 (2008)","journal-title":"Qual. Life Res."},{"key":"486_CR3","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/ard.2007.081604","volume":"67","author":"JA Singh","year":"2008","unstructured":"Singh, J.A., Strand, V.: Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann. Rheum. Dis. 67, 1310\u20131316 (2008)","journal-title":"Ann. Rheum. Dis."},{"key":"486_CR4","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3899\/jrheum.071229","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker, M.A., Schumacher, H.R., Benjamin, K.L., et al.: Quality of life and disability in patients with treatment-failure gout. J. Rheumatol. 36, 1041\u20131048 (2009)","journal-title":"J. Rheumatol."},{"key":"486_CR5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1524-4733.2007.00173.x","volume":"10","author":"NL Kleinman","year":"2007","unstructured":"Kleinman, N.L., Brook, R.A., Patel, P.A., et al.: The impact of gout on work absence and productivity. Value Health 10, 231\u2013237 (2007)","journal-title":"Value Health"},{"issue":"1","key":"486_CR6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/RHU.0b013e3181945d2c","volume":"15","author":"R Halpern","year":"2009","unstructured":"Halpern, R., Fuldeore, M.J., Mody, R.R., et al.: The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol 15(1), 3\u20137 (2009)","journal-title":"J Clin Rheumatol"},{"key":"486_CR7","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3899\/jrheum.080487","volume":"36","author":"EQ Wu","year":"2009","unstructured":"Wu, E.Q., Patel, P.A., Mody, R.R., et al.: Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J. Rheumatol. 36, 1032\u20131040 (2009)","journal-title":"J. Rheumatol."},{"key":"486_CR8","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1185\/030079906X112606","volume":"22","author":"RA Brook","year":"2006","unstructured":"Brook, R.A., Kleinman, N.L., Patel, P.A., et al.: The economic burden of gout on an employed population. Curr. Med. Res. Opin. 22, 1381\u20131389 (2006)","journal-title":"Curr. Med. Res. Opin."},{"key":"486_CR9","first-page":"164","volume":"14","author":"EQ Wu","year":"2008","unstructured":"Wu, E.Q., Patel, P.A., Yu, A.P., et al.: Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm. 14, 164\u2013175 (2008)","journal-title":"J Manag Care Pharm."},{"key":"486_CR10","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3899\/jrheum.080768","volume":"36","author":"JG Hanly","year":"2009","unstructured":"Hanly, J.G., Skedgel, C., Sketris, I., et al.: Gout in the elderly\u2014a population health study. J. Rheumatol. 36, 822\u2013830 (2009)","journal-title":"J. Rheumatol."},{"key":"486_CR11","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/ard.2007.076232","volume":"67","author":"L Annemans","year":"2008","unstructured":"Annemans, L., Spaepen, E., Gaskin, M., et al.: Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000\u20132005. Ann. Rheum. Dis. 67, 960\u2013966 (2008)","journal-title":"Ann. Rheum. Dis."},{"key":"486_CR12","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/ard.2004.024091","volume":"64","author":"TR Mikuls","year":"2005","unstructured":"Mikuls, T.R., Farrar, J.T., Bilker, W.B., et al.: Gout epidemiology: results from the UK General Practice Research Database, 1990\u20131999. Ann. Rheum. Dis. 64, 267\u2013272 (2005)","journal-title":"Ann. Rheum. Dis."},{"key":"486_CR13","first-page":"577","volume":"28","author":"J Li-Yu","year":"2001","unstructured":"Li-Yu, J., Clayburne, G., Sieck, M., et al.: Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J. Rheumatol. 28, 577\u2013580 (2001)","journal-title":"J. Rheumatol."},{"key":"486_CR14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","volume":"51","author":"A Shoji","year":"2004","unstructured":"Shoji, A., Yamanaka, H., Kamatani, N.: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 51, 321\u2013325 (2004)","journal-title":"Arthritis Rheum."},{"issue":"suppl 2","key":"486_CR15","doi-asserted-by":"crossref","first-page":"ii9","DOI":"10.1093\/rheumatology\/kep087","volume":"48","author":"F Perez-Ruiz","year":"2009","unstructured":"Perez-Ruiz, F.: Treating to target: a strategy to cure gout. Rheumatology (Oxford) 48(suppl 2), ii9\u2013ii14 (2009)","journal-title":"Rheumatology (Oxford)"},{"key":"486_CR16","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang, W., Doherty, M., Bardin, T., et al.: EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 65, 1312\u20131324 (2006)","journal-title":"Ann. Rheum. Dis."},{"key":"486_CR17","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","volume":"46","author":"KM Jordan","year":"2007","unstructured":"Jordan, K.M., Cameron, J.S., Snaith, M., et al.: British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 46, 1372\u20131374 (2007)","journal-title":"Rheumatology (Oxford)"},{"key":"486_CR18","unstructured":"Cegedim Strategic Data UK Ltd.: Data on File. (2010)"},{"key":"486_CR19","unstructured":"A. Menarini Pharma UK SRL: Adenuric Film-Coated Tablets. Summary of Product Characteristics. 12 May 2011. http:\/\/www.medicines.org.uk\/emc\/document.aspx?documentId=22830#CLINICAL_PARTS . Date last accessed 3 Nov 2011"},{"key":"486_CR20","unstructured":"National Institute for Health and Clinical Excellence: Final Appraisal Determination. Febuxostat for the Management of Hyperuricaemia in People with Gout NICE. Aug 2008. http:\/\/www.nice.org.uk\/nicemedia\/live\/11830\/41648\/41648.pdf . Date last accessed 3 Nov 2011"},{"key":"486_CR21","unstructured":"Scottish Medicines Consortium: Febuxostat 80\u00a0mg and 120\u00a0mg Tablets (Adenuric\u00ae) SMC No. 637\/10. 6 Aug 2010. http:\/\/www.scottishmedicines.org.uk\/files\/advice\/febuxostat-Adenuric-FINAL-August-2010.pdf . Date last accessed 3 Nov 2011"},{"key":"486_CR22","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher Jr, H.R., Becker, M.A., Wortmann, R.L., et al.: Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 59, 1540\u20131548 (2008)","journal-title":"Arthritis Rheum."},{"key":"486_CR23","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker, M.A., Schumacher Jr, H.R., Wortmann, R.L., et al.: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 353, 2450\u20132461 (2005)","journal-title":"N. Engl. J. Med."},{"key":"486_CR24","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker, M.A., Schumacher, H.R., MacDonald, P.A., et al.: Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout. J. Rheumatol. 36, 1273\u20131282 (2009)","journal-title":"J. Rheumatol."},{"key":"486_CR25","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker, M.A., Schumacher, H.R., Espinoza, L.R., et al.: The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12, R63 (2010). doi: 10.1186\/ar2978","journal-title":"Arthritis Res Ther"},{"key":"486_CR26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","volume":"48","author":"HR Schumacher Jr","year":"2009","unstructured":"Schumacher Jr, H.R., Becker, M.A., Lloyd, E., et al.: Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 48, 188\u2013194 (2009)","journal-title":"Rheumatology (Oxford)"},{"key":"486_CR27","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","volume":"52","author":"MA Becker","year":"2005","unstructured":"Becker, M.A., Schumacher Jr, H.R., Wortmann, R.L., et al.: Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 52, 916\u2013923 (2005)","journal-title":"Arthritis Rheum."},{"key":"486_CR28","unstructured":"Ipsen, U.K.: Integrated Summary of Efficacy. Data on File. (2005)"},{"key":"486_CR29","unstructured":"Institute of Medical Science World Publications Ltd: A Health Economic Assessment of Febuxostat in the Management of Gout. Data on File. Version No. 1.0, 19 Oct 2007"},{"key":"486_CR30","unstructured":"BMJ Publishing Group Ltd., RCPCH Publications Ltd., Royal Pharmaceutical Society of Great Britain: British National Formulary. http:\/\/bnf.org\/bnf\/bnf\/current\/index.htm . (2011)"},{"key":"486_CR31","unstructured":"Office for National Statistics: Mortality Statistics. Deaths Registered in 2007"},{"key":"486_CR32","unstructured":"Scottish Medicines Consortium: Guidance to Manufacturers for Completion of New Product Assessment Form (NPAF). June 2011. http:\/\/www.scottishmedicines.org.uk\/files\/submissionprocess\/New_Product_Assessment_Form_NPAF_Guidance_Notes_updated_February_2011_Final.doc . Date last accessed 3 Nov 2011"},{"key":"486_CR33","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/ard.2007.070755","volume":"66","author":"E Roddy","year":"2007","unstructured":"Roddy, E., Zhang, W., Doherty, M.: Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann. Rheum. Dis. 66, 1311\u20131315 (2007)","journal-title":"Ann. Rheum. Dis."},{"key":"486_CR34","unstructured":"National Institute for Health and Clinical Excellence: Guide to the Methods of Technology Appraisal. June 2008. http:\/\/www.nice.org.uk\/media\/B52\/A7\/TAMethodsGuideUpdatedJune2008.pdf Date last accessed 3 Nov 2011"},{"issue":"12","key":"486_CR35","first-page":"2429","volume":"31","author":"GC Borstad","year":"2004","unstructured":"Borstad, G.C., Bryant, L.R., Abel, M.P., et al.: Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J. Rheumatol. 31(12), 2429\u20132432 (2004)","journal-title":"J. Rheumatol."},{"key":"486_CR36","unstructured":"Ipsen, U.K.: Febuxostat for the Treatment of Gout Single Technology Appraisal Submission to the National Institute for Health and Clinical Excellence. 14 May 2008. http:\/\/www.nice.org.uk\/nicemedia\/live\/11830\/40731\/40731.pdf . Date last accessed 3 Nov 2011"},{"key":"486_CR37","doi-asserted-by":"crossref","unstructured":"Jackson, T.: Cost Analysis of Febuxostat Versus Allopurinol for Prophylaxis of Gout Flares. In: Poster presented at the 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Washington, DC, June 2\u20136 2012","DOI":"10.1016\/j.jval.2012.03.204"},{"issue":"3","key":"486_CR38","doi-asserted-by":"crossref","first-page":"A123","DOI":"10.1016\/S1098-3015(10)72594-8","volume":"13","author":"E Jutkowitz","year":"2010","unstructured":"Jutkowitz, E., Pizzi, L., Meltzer, M.: Comparison of cost of allopurinol vs febuxostat as a first line treatment for gout. Value Health 13(3), A123 (2010)","journal-title":"Value Health"},{"issue":"7","key":"486_CR39","doi-asserted-by":"crossref","first-page":"A435","DOI":"10.1016\/S1098-3015(10)75153-6","volume":"12","author":"BJ Pandya","year":"2009","unstructured":"Pandya, B.J., Quimbo, R.A., Mody, R., et al.: Budgetary impact of a new urate-lowering therapy (ULT) for the treatment of gout in a US health plan formulary. Value Health 12(7), A435 (2009)","journal-title":"Value Health"},{"issue":"3","key":"486_CR40","doi-asserted-by":"crossref","first-page":"A126","DOI":"10.1016\/S1098-3015(10)72608-5","volume":"13","author":"N Rashid","year":"2010","unstructured":"Rashid, N., Hay, J.W.: Cost effectiveness analysis of managing chronic gout with febuxostat (Uloric) versus allopurinol (Zyloprim). Value Health 13(3), A126 (2010)","journal-title":"Value Health"},{"issue":"2","key":"486_CR41","first-page":"e195","volume":"18","author":"L Redding","year":"2011","unstructured":"Redding, L., Hornberger, J., Cowens, W., et al.: Cost-effectiveness of febuxostat in managing hyperuricemia in gout patients in Canada. J Popul Ther Clin Pharmacol 18(2), e195\u2013e196 (2011)","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"486_CR42","unstructured":"Stevenson, M., Pandor, A.: Hyperuricaemia\u2014febuxostat: Evidence Review Group Report. Febuxostat for the Management of Hyperuricaemia in Patients with Gout. 31 March 2008. http:\/\/www.nice.org.uk\/nicemedia\/live\/11830\/40721\/40721.pdf . Date last accessed 3 Nov 2011"},{"key":"486_CR43","unstructured":"Stevenson, M., Pandor, A.: Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal. Health Technol. Assess. 13(suppl 3), 37\u201342 (2009). http:\/\/www.hta.ac.uk\/erg\/supplements\/supplement1303.pdf#nameddest=article06 . Date last accessed 3 Nov 2011"},{"key":"486_CR44","doi-asserted-by":"crossref","unstructured":"Stevenson, M., Pandor, A.: Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal. Pharmacoeconomics 29(2), 133\u2013140 (2011). http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21155617 . Date last accessed 3 Nov 2011","DOI":"10.2165\/11535770-000000000-00000"},{"key":"486_CR45","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","volume":"68","author":"MK Reinders","year":"2009","unstructured":"Reinders, M.K., Haagsma, C., Jansen, T.L., et al.: A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300\u2013600\u00a0mg\/day versus benzbromarone 100\u2013200 mg\/day in patients with gout. Ann. Rheum. Dis. 68, 892\u2013897 (2009)","journal-title":"Ann. Rheum. Dis."},{"key":"486_CR46","first-page":"582","volume":"48","author":"SJ Lee","year":"2009","unstructured":"Lee, S.J., Hirsch, J.D., Terkeltaub, R., et al.: Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford) 48, 582\u2013586 (2009)","journal-title":"Rheumatology (Oxford)"},{"key":"486_CR47","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s11136-010-9690-9","volume":"19","author":"MM Groen van","year":"2010","unstructured":"van Groen, M.M., ten Klooster, P.M., Taal, E., et al.: Application of the health assessment questionnaire disability index to various rheumatic diseases. Qual. Life Res. 19, 1255\u20131263 (2010)","journal-title":"Qual. Life Res."},{"key":"486_CR48","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/rheumatology\/kem246","volume":"46","author":"N Dalbeth","year":"2007","unstructured":"Dalbeth, N., Collis, J., Gregory, K., et al.: Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology (Oxford) 46, 1804\u20131807 (2007)","journal-title":"Rheumatology (Oxford)"},{"key":"486_CR49","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2165\/00003495-200666120-00002","volume":"66","author":"GG Teng","year":"2006","unstructured":"Teng, G.G., Nair, R., Saag, K.G.: Pathophysiology, clinical presentation and treatment of gout. Drugs 66, 1547\u20131563 (2006)","journal-title":"Drugs"},{"key":"486_CR50","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/archinte.164.14.1546","volume":"164","author":"LK Niskanen","year":"2004","unstructured":"Niskanen, L.K., Laaksonen, D.E., Nyyssonen, K., et al.: Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch. Intern. Med. 164, 1546\u20131551 (2004)","journal-title":"Arch. Intern. Med."}],"updated-by":[{"DOI":"10.1007\/s10198-014-0617-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,6,18]],"date-time":"2014-06-18T00:00:00Z","timestamp":1403049600000}}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-013-0486-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10198-013-0486-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-013-0486-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T07:02:58Z","timestamp":1559113378000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10198-013-0486-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,30]]},"references-count":50,"alternative-id":["486"],"URL":"https:\/\/doi.org\/10.1007\/s10198-013-0486-z","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,30]]}}}